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Abstract The thioredoxin-catalyzed insulin reduction by dihy- 
drolipoate was applied to study the 2-oxoacid:lipoate oxidore- 
ductase activity of 2-oxoacid dehydrogenase complexes. The 
enzymatic and non-enzymatic mechanisms of the transfer of re- 
ducing equivalents from the complexes to free lipoic acid (a-lipoic 
acid, 6,8-thiooctic acid) were distinguished using the high 
stereoselectivity of the complex enzymes to the R-enantiomer of 
lipoate. Unlike these enzymes, thioredoxin from E. coli exibited 
no stereoselectivity upon reduction with chemically obtained ihy- 
drolipoate. However, coupled to the dihydrolipoate production by 
the dehydrogenase complexes, the process was essentially sensi- 
tive both to the enantiomer used and the dihydrolipoyl dehydroge- 
nase activity of the complexes. These results indicated the in- 
volvement of the third complex component, dihydrolipoyl dehy- 
drogenase, in the 2-oxoacid-dependent dihydrolipoate formation. 
The implication of the investigated reaction for a connection 
between thioredoxin and the 2-oxoacid ehydrogenase complexes 
in the mitochondrial metabolism are discussed. 
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Introduction 
Recently we have started the investigation of the interplay 
between dehydrogenases of 2-oxoacids and thioredoxins [1]. 
The dehydrogenases are multienzyme mitochondrial complexes 
known to utilize pyruvate, 2-oxoglutarate or branched chain 
2-oxoacids in the sequence of Reactions I-3 [2]: 
2-oxoacid + (S-S)-Iip-E2 .... E1 ---) CO 2 "~- (acyl-S-SH)-lip-E2 (1) 
(acyl-S-SH)-lip-E2 + CoA e- E2 -~ acylCoA + (SH)2-1ip-E2 (2) 
(SH)2-1ip-E2 + NAD ÷ ~ E3 ---) (S-S)-lip-E2 + NADH + H (3) 
where E1 is a thiamindiphosphate-dependent dehydrogenase; 
E2, dihydrolipoyl transacylase; E3, dihydrolipoyl dehydroge- 
*Corresponding author. 
Abbreviations." DTNB, 5,5'-dithio-bis-(2-nitrobenzoic) acid; CoA, Co- 
enzyme A. 
nase; and lip represents the lipoyl residue functioning in the 
complexes covalently bound to the E2 component. 
Thioredoxins belong to a family of small redox proteins 
involved in a variety of physiologically important functions due 
to their ability to serve as hydrogen donor or to reduce disul- 
fides in proteins [3]. 
Our study was induced by the discovery of the specific mito- 
chondrial thioredoxin [4] and the known fact that the similar 
thioredoxin of E. coli can be effectively reduced by dihydro- 
lipoate [5]. Because the latter is an intermediate of the 2-oxoacid 
oxidation occuring in mitochondria, we checked whether the 
organelle-specific redox transformation of thioredoxin may be 
coupled to the 2-oxoacid oxidation. Indeed, the E. coli thiore- 
doxin becomes reduced at the expense of 2-oxoacid oxidized by 
mitochondrial 2-oxoacid dehydrogenase complexes [1]. This 
occurs through dihydrolipoate formed if NAD ÷, the terminal 
electron acceptor in the complex-catalyzed r action, is omitted 
and replaced by free lipoate. In this case Reaction 3 of the 
overall 2-oxoacid oxidation is substituted by Reaction 4: 
(SH)2-1ip-E2 + (S-S)-lip *-* (S-S)-lip-E2 + (SH)~-lip (4) 
where the covalently bound lipoyl cofactor becomes reoxidized 
by free lipoic acid. 
Coupling 2-oxoacid oxidation to the thioredoxin redox cycle 
with insulin [1] provides an assay for characterizing the lipoate- 
reductase activity of the 2-oxoacid ehydrogenase complexes. 
This system was used in the present work to reveal the mecha- 
nism of Reaction 4. 
Reaction 4 may be catalyzed by E3, since this component is
able to store the reducing equivalents by the FAD-Cys-Cys- 
center at its active site [6]. Thus, reduced lipoyl cofactor and 
free lipoate may bind, one after the other, to the same site of 
E3, exchanging their reducing equivalents. Alternatively, un- 
catalyzed thiol-disulfide exchange between theE2-bound dihy- 
drolipoate and free lipoate may occur. 
The mechanisms were distinguished using the high stereose- 
lectivity of E3 to the R-enantiomer of lipoate [7 9]. We showed, 
that unlike this enzyme, the E. coli thioredoxin exhibits no 
stereoselectivity upon reduction with chemically obtained ster- 
eomers of dihydrolipoate. The coupled system, however, was 
essentially sensitive both to the enantiomer used and the E3 
activity of the complexes, pointing to the involvement of E3 in 
the dihydrolipoate formation in Reaction 4. 
Our present results indicate that the native organization of 
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the 2-oxoacid dehydrogenase complexes, including all three 
catalytic omponents, is necessary for the reduction of lipoic 
acid, while non-enzymatic thiol-disulfide exchange between the 
complex-bound and free lipoic acid is unable to support the 
observed reaction. 
2. Materials and methods 
The 2-oxoglutarate and pyruvate dehydrogenase complexes were 
obtained from pig heart according to [10] applying the modifications 
described in [1]. 
2-Oxoacid-dependent r duction of thioredoxin was determined in a 
Cary-219 spectrophotometer by the insulin turbidimetric assay [5] as 
described in [1]. The reaction was measured in0.1 M potassium phos- 
phate pH 7.0 containing 0.7 mg/ml insulin and 0.15 mg/ml thioredoxin 
against the blank with all the components but thioredoxin. In addition 
to this the test mixture for the 2-oxoglutarate dehydrogenase-dependent 
reaction contained 0.049 U of the 2-oxoglutarate d hydrogenase com- 
plex activity (measured with NAD + in the standart assay mixture), 1.5 
mM 2-oxoglutarate, 0.6 mM CoA and 3 mM lipoate or analogs. Cor- 
respondingly, the pyruvate dehydrogenase-dependent reaction mixture 
contained 0.010 U of the pyruvate dehydrogenase complex activity 
(measured with NAD÷), 15 mM pyruvate, 0.3 mM CoA, 0.76 mM 
magnesium chloride, 0.15 mM thiamin diphosphate and 3 mM lipoate 
or analogs. 
R- and S-Dihydrolipoate were freshly prepared from their oxidized 
forms by sodium borohydride r duction by the following procedure. 0.5
ml of 2.5% sodium borohydride in water was added to 30 mg of the 
corresponding lipoic acid enantiomer dissolved in 0.5 ml of 0.1 M 
Tris-HC1 buffer pH 8.5. After 30 min incubation at room temperature 
0.25 ml of 1 M potassium phosphate containing 0.2 N HCI was added. 
The mixture was left o stand at room temperature for 15 min and 1 
ml of acetone was added. The completion of the reaction and the 
concentration f dihydrolipoate formed were determined by DTNB 
titration. For measuring the thioredoxin-mediated insulin reduction 
this dihydrolipoate solution was diluted 20-fold. 
Inhibition of 2-oxoglutarate d hydrogenase complex by diphenylio- 
donium chlorid was studied after 80 rain incubation ofthe enzyme with 
the inhibitor in the presence of 0.2 mM NADH, followed by gel- 
filtration on the PD-10 column with Sephadex G-25 medium (Pharma- 
cia) for removing the excess of diphenyliodonium chlorid and NADH. 
The 2-oxoglutarate and pyruvate dehydrohenase complex activities 
were determined in 0.1 M potassium phosphate at pH 7.0 and 7.6, 
respectively, with 2 mM 2-oxoglutarate or pyruvate, 0.1 mM CoA, 1 
mM NAD ÷, 0.1 mM thiamin diphosphate and 1 mM magnesium chlo- 
ride. The E 1 activity of 2-oxoglutarate d hydrogenase was assayed with 
0.7 mM ferricyanide and 1 mM 2-oxoglutarate in 0.1 M potassium 
phosphate pH 6.3. The E3 activity was determined with 0.2 mM NADH 
and 1 mM R,S-lipoate in 0.1 M potassium phosphate pH 6.3. 
Thioredoxin of E. coli was from Calbiochem; insulin, R,S-lipoic acid, 
thiamin diphosphat, CoA were from Serva; 2-oxoglutarate, pyruvate 
and DTNB - from Merck, diphenyliodonium chloride was from ICN. 
The lipoate nantiomers and analogs were from ASTA Medica AG, 
Frankfurt. 
3. Results 
Reactions of the pyruvate and 2-oxoglutarate dehydrogenase 
complexes (Reactions 1-2) coupled to the thioredoxin-insulin 
assay in the presence of lipoate enantiomers and analogs are 
shown in Fig. 1. In this test system dihydrolipoate accumulated 
according to Reaction 4 reduces thioredoxin (Reaction 5): 
(SH)2-1ip + (S-S)-thioredoxin ,--, (SH)2-thioredoxin + (S-S)-lip (5) 
Reduced thioredoxin catalyzes reduction of insulin in Reac- 
tion 6: 
(SH)2-thioredoxin + (S-S)-Insulin ~ (SH)2-Insulin + (S-S)- 
thioredoxin (6) 
Reduced insulin precipitates in the reaction medium and the 
increase in the optical density is followed (Fig. 1). The reaction 
proceeds at  considerable rate both with the pyruvate (Fig. la) 
and 2-oxoglutarate (Fig. lb) dehydrogenase complexes only 
in the presence of the R-enantiomer of lipoate (curves 1), 
while no reaction could be observed with the S-enantiomer 
(curves 2). 
To differentiate whether this outcome reflected only the ster- 
eospecificity of the lipoate reduction (Reaction 4) or whether 
the subsequent thioredoxin reduction (Reaction 5) also contrib- 
uted to the observed stereoselectivity, he thioredoxin-mediated 
insulin precipitation (Reactions 5 and 6) was studied in the 
presence of chemically obtained R- or S-dihydrolipoate. The 
results of this experiment are shown in Fig. 2. Thioredoxin had 
no preference for the R-enantiomer in insulin reduction (curve 
1), rather S-dihydrolipoate appeared tdo be slightly more effi- 
cient (curve 2). Obviously, the stereoselectivity of the 2- 
oxoacid-dependent i sulin precipitation (Fig. 1) is not deter- 
mined by any thioredoxin stereospecificity. Thus, it is the step 
of lipoate reduction (Reaction 4) which is stereoselective. 
Structural homologs bis- and tetranorlipoate, with carbon 
chains being 2 and 4 atoms, respectively, shorter than lipoate, 
were also tested with the 2-oxoacid dehydrogenase complexes 
in the thioredoxin-mediated insulin precipitation assay (Fig. 
la,b, curves 34) .  These analogs, like S-lipoate, showed only 
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Fig. 1. Insulin reduction by E. eoli thioredoxin coupled to the pyruvate (a) or 2-oxoglutarate (b)dehydrogenase complexes in the presence of lipoate 
and analogs. 1, R-lipoate; 2, S-lipoate; 3, bisnorlipoate; 4, tetranorlipoate. See section 2 for experimental conditions. 
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3-5% of the E3 activity with the R-enantiomer: Their weak 
activities as ubstrates in the dihydrolipoate dehydrogenase 
reaction correlate with their inefficiency in the 2-oxoacid-de- 
pendent thioredoxin reduction: the insulin precipitation i the 
presence of analogs is negligible in comparison to that with 
R-lipoate (Fig. 1). 
The dependence of the reduction of free lipoate in the insulin 
reduction test on the E3 activity of the 2-oxoacid dehydro- 
genase complexes was further supported by experiments in 
which E3 was specifically inhibited by diphenyliodonium chlo- 
rid. This compound is an inhibitor of FAD-dependent dehy- 
drogenases, forming a tight complex with FAD upon its reduc- 
tion during a catalytic process [11-13]. Indeed, treatment of the 
2-oxoglutarate d hydrogenase complex with the inhibitor alone 
produced no inhibition. However, incubation with diphenylio- 
donium chlorid in the presence of NADH led to the concomi- 
tant loss of the E3 and overall activities of the complex, while 
the E1 activity was not decreased (Table 1). The insulin reduc- 
tion test demonstrated that the activity of the diphenylio- 
donium chloride-treated 2-oxoglutarate dehydrogenase com- 
plex in dihydrolipoate production waslost to the same extent 
as its E3 activity: compared to the native enzyme complex, the 
inhibited one showed the five times slower rate of the insulin 
precipitation, correspondent to the five-fold inhibition of the 
E3 activity (Table 1). 
4. Discussion 
The results presented in this work ruled out the possibility 
of the effective non-enzymatic thiol-disulfide exchange between 
the E2-bound and free dihydrolipoate, since there is no differ- 
ence in the redox potentials of both lipoic acid enantiomers and 
such a reaction should not depend on the nature of the enanti- 
omer. Moreover, all used compounds with dithiolane ring are 
to undergo redox transformation with similar efficiency, but 
considerable r duction proceeds only with R-lipoic acid, point- 
ing to the nzymatic atalysis of the process (Fig. 1). 
Dihydrolipoyl dehydrogenase i  known to be highly specific 
to R-lipoate, showing practically no activity with the S-enanti- 
omer [7-9]. Taking into account he normal course of the cata- 
lytic steps in the 2-oxoacid dehydrogenase complexes, with 
E2-bound dihydrolipoate reducing E3, our data point to the 
fact that the E3 component of these enzyme complexes must 
catalyze Reaction 4. According to this mechanism, the E2- 
bound dihydrolipoate r duces E3, resulting in the formation of 
the E2-bound lipoate and the two-electron reduced E3 as a 
catalytic intermediate. After the oxidized E2-bound lipoyl 
moiety has left its E3 binding site, free lipoate from the medium 
Table 1 
Changes in the 2-oxoglutarate d hydrogenase complex activities due to 
the treatment of the complex with dipheniliodonium chloride* 
Preparation Activity 
Overall E 1 E3 Thioredoxin- 
(reactions insulin 
1-3) reduction 
Control 100 100 100 100 
Diphenyliodonium 
chloride-treated complex 37 142 17 24 
*For experimental conditions see section 2.
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Fig. 2. Insulin reduction by £ coli thioredoxin (0.05 mg/ml) dependent 
on dihydrolipoate enantiomers (0.37 mM). Curve 1, R-dihydrolipoate; 
curve 2, S-dihydrolipoate; curve 3, R,S-dihydrolipoate. 
may interact with the reduced E3 intermediate accepting the 
reducing equivalents and reoxidizing the enzyme. 
Dihydrolipoyl acetyltransferase of the pyruvate dehydro- 
genase complex shows also stereoselectivity for R-lipoate [8,14]. 
However, this enzyme cannot execute the reduction of lipoate, 
since the formation of the two electron-reduced nzyme in this 
case is not possible and each active site of E2 contains only one 
binding site for the lipoate moiety [15,16]. This argues against 
the assumption that Reaction 4may proceed in the active center 
of E2. 
Thus, the lipoate-mediated thioredoxin reduction needs the 
sequential work of all three catalytic omponents of the 2- 
oxoacid dehydrogenase complexes. This supports the possible 
physiological significance of the functional interplay between 
the dehydrogenases of 2-oxoacids and mitochondrial thiore- 
doxin, since the thioredoxin may be reduced in mitochondria 
by the existing catalytic unit for the 2-oxoacid oxidation. With 
lipoate as the terminal electron acceptor instead of NAD +, the 
latter process may be coupled to the pathways utilizing its 
energy through the reduced thioredoxin. Such a possibility ap- 
pears even more probable, if we take into account the high 
protein concentration i side the mitochondria long with the 
large number of mitochondrial dehydrogenases competing for 
NAD+: this makes the fact obvious that in vivo the 2-oxoacid 
dehydrogenase complexes do not operate under NAD+-satu - 
rated conditions, but are allowed to participate in the reduction 
of physiologically occuring lipoate. 
Mitochondrial thioredoxin reduced at the expense of 2- 
oxoacid could play an important role in mitochondrial DNA 
synthesis, viz. by providing reducing equivalents for the forma- 
tion of 2'-deoxyribonucleotide pools catalyzed by a presumed 
organelle-located ribonucleotide r ductase [17]. 
The 2-oxoacid-dependent lipoate-reductase activity of the 
enzyme complexes tudied in this work should be taken into 
account when investigating the lipoate effect upon operating 
complexes. Such an investigation done with pyruvate dehydro- 
genase complexes from various ources howed different effects 
of R- and S-lipoate [9]. The possibility of the R-lipoate reduc- 
tion by the complexes might be responsible for the observed 
difference, since the system with the R-enantiomer is able to 
reduce it and will contain therefore both the oxidized and re- 
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duced forms of lipoate, while in case of the S-enantiomer only 
the oxidized form is present. 
Thus, the lipoate reductase activity of the 2-oxoacid ehydro- 
genase complexes has implications for understanding both the
functioning of the complexes and their integration i  the differ- 
ent pathways of mitochondrial metabolism. 
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